Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
) 
    $(121,022) 
    $37,340 
  
    Stock-based compensation 
     -  
     -  
     1,779  
                    -  
     -  
     1,779 
  
    Gain on foreign currency translation 
     -  
     -  
     -  
     130  
     -  
     130 
  
    Net loss 
     -  
     -  
     -  
     -  
     (11,025) 
     (11,025)
  
    Balance as of March 31, 2024 
     17,950,776  
     18  
     160,922  
     (669) 
     (132,047) 
     28,224 
  
    Stock-based compensation 
     -  
     -  
     2,350  
     -  
     -  
     2,350 
  
    Common stock issued for cash 
     198,364  
     -  
     2,032  
     -  
     -  
     2,032 
  
    Common stock and warrants issued for cash 
     1,557,592  
     2  
     13,463  
     -  
     -  
     13,465 
  
    Loss on foreign currency translation 
     -  
     -  
     -  
     (44) 
     -  
     (44)
  
    Net loss 
     -  
     -  
     -  
     -  
     (9,746) 
     (9,746)
  
    Balance as of June 30, 2024 
     19,706,732  
    $20  
    $178,767  
    $(713) 
    $(141,793) 
    $36,281 

The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.

4

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

    For the Six Months Ended June 30, 

    2025